drugset / Trial / NCT02213107

Enzalutamide & Dutasteride/Finasteride as 1st Line Treatment for Patients =/> 65 Years Old With Prostate Cancer.

NCT02213107

Phase 2 Completed 43 enrolled University of Rochester
NaSingle-groupOpen-labelTreatment

Summary

Determine the effect of enzalutamide and dutasteride or finasteride on the time to prostatic-specific antigen level increase in patients age 65 or older.

Timeline

Start
2014-09
Primary completion
2023-10-31
Completion
2023-10-31

Drugs

EvaluationDrugModalityDoseRoute
Subject Dutasteride Small molecule Oral
Subject Enzalutamide Other / unclassified Oral
Subject Finasteride Small molecule Oral

Indications